---
title: "Mayne Pharma Issues New Shares on Conversion of Unquoted Equity Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271604867.md"
description: "Mayne Pharma Group has issued 25,592 new ordinary shares following the conversion of unquoted equity securities, effective December 31, 2025. This increase in issued capital slightly dilutes existing shareholders and indicates the company's ongoing use of equity-based funding typical in the pharmaceutical sector. The latest analyst rating for Mayne Pharma (AU:MYX) is a Buy, with a price target of A$6.10. The company specializes in developing and manufacturing branded and generic medicines, focusing on complex products for the Australian and U.S. markets."
datetime: "2026-01-06T05:08:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271604867.md)
  - [en](https://longbridge.com/en/news/271604867.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271604867.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/271604867.md) | [繁體中文](https://longbridge.com/zh-HK/news/271604867.md)


# Mayne Pharma Issues New Shares on Conversion of Unquoted Equity Securities

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Mayne Pharma Group ( (AU:MYX) ) has issued an update.

Mayne Pharma Group Limited has notified the market of the issue of 25,592 new ordinary fully paid shares following the conversion or exercise of previously unquoted equity securities, effective 31 December 2025. The modest increase in issued capital reflects the crystallisation of existing equity incentives or convertible instruments, marginally diluting existing shareholders while signalling ongoing utilisation of equity-based funding and remuneration typical for companies in the pharmaceutical sector.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

**More about Mayne Pharma Group**

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company listed on the ASX under the code MYX. The company develops and manufactures branded and generic medicines, with a focus on complex and hard-to-formulate products for markets including Australia and the United States.

**Average Trading Volume:** 569,690

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$259.2M

See more insights into MYX stock on TipRanks’ Stock Analysis page.

## Related News & Research

- [Semarion Secures $3.8 Million to Scale Next-Generation Cell Assay Technology and Accelerate Pharma Adoption](https://longbridge.com/en/news/281152196.md)
- [Aurobindo Pharma to consider buyback of equity shares](https://longbridge.com/en/news/281214424.md)
- [UK reaches agreement with US for British drugs to be tariff free](https://longbridge.com/en/news/281563745.md)
- [Glenmark Pharma gets tax demand and penalty of 160.5 million rupees each](https://longbridge.com/en/news/281382178.md)
- [US tariffs on medicines decoded: Why Washington wants pharma production back](https://longbridge.com/en/news/281610845.md)